6550.TW Polaris Group
- Market cap
- TWD 6.37B
- P/E
- -
- P/B
- 1.40x
- ROE
- -61.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6550.TW undervalued?
Graham numberThe Graham number of Polaris Group cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Polaris Group fundamental analysis
No fundamental analysis for Polaris Group yet.
Polaris Group stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Polaris Group
Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Cayman Islands.
Full company profilePolaris Group financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Polaris Group annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 9.41M | 15.0M | 6.44M | 7.48M | 107M | 40.6M | 88.4M |
| Gross Profit | -128M | -114M | -111M | -138M | -131M | -151M | -142M | -138M | -76.9M | -270M | -505M |
| Operating Income | -948M | -844M | -1.01B | -795M | -678M | -732M | -1.16B | -1.85B | -2.63B | -2.88B | -2.17B |
| EBITDA | -802M | -739M | -887M | -655M | -522M | -571M | -990M | -1.41B | -2.17B | -2.50B | -1.76B |
| Net Income | -982M | -898M | -1.03B | -830M | -660M | -740M | -1.15B | -1.58B | -2.50B | -3.95B | -2.80B |
| EPS | -7.98 | -6.94 | -6.89 | -4.75 | -1.95 | -2.10 | -3.03 | -4.09 | -6.45 | -9.87 | -6.17 |
| Balance Sheet | |||||||||||
| Total Assets | 1.97B | 2.22B | 1.98B | 4.11B | 3.36B | 7.82B | 9.22B | 9.10B | 9.09B | 8.17B | 7.38B |
| Total Liabilities | 1.73B | 1.22B | 1.34B | 497M | 481M | 608M | 545M | 1.46B | 2.32B | 2.87B | 2.84B |
| Shareholders' Equity | 207M | 1.00B | 641M | 3.61B | 2.88B | 7.21B | 8.67B | 7.37B | 6.70B | 5.30B | 4.54B |
| Cash & Short-term Investments | 358M | 707M | 395M | 2.62B | 1.85B | 6.33B | 7.38B | 4.95B | 3.12B | 2.74B | 2.30B |
| Total Debt | 1.52B | 1.01B | 1.03B | 276M | 326M | 437M | 383M | 1.20B | 1.88B | 2.35B | 2.36B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -783M | -708M | -779M | -748M | -586M | -539M | -1.03B | -1.26B | -2.03B | -2.39B | -1.83B |
| Capital Expenditure | 305M | 20.7M | 43.2M | 50.2M | 51.7M | 204M | 69.6M | 333M | 1.66B | 795M | 260M |
| Free Cash Flow | -1.09B | -729M | -822M | -798M | -637M | -744M | -1.10B | -1.59B | -3.69B | -3.19B | -2.06B |
| Ratios | |||||||||||
| ROE | -473.9% | -89.8% | -161.2% | -23.0% | -22.9% | -10.3% | -13.3% | -21.4% | -37.4% | -74.5% | -61.7% |
| ROA | -49.9% | -40.4% | -52.2% | -20.2% | -19.6% | -9.5% | -12.5% | -17.3% | -27.5% | -48.3% | -38.0% |
| Net Profit Margin | - | - | - | - | -7,016.2% | -4,923.1% | -17,866.6% | -21,076.0% | -2,338.9% | -9,716.5% | -3,171.3% |
| Debt to Equity | 7.32x | 1.01x | 1.61x | 0.08x | 0.11x | 0.06x | 0.04x | 0.16x | 0.28x | 0.44x | 0.52x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Polaris Group dividends
Polaris Group has not paid dividends in the last 9 fiscal years.
Last stock split: 519.5017:1000 on Sep 17, 2026.
Who owns Polaris Group
- Insiders 66.98%
- Institutions 1.20%
- Public & others 31.82%
- Shares outstanding 465M
- Free float 153M
Polaris Group company profile
- Company name
- Polaris Group
- Ticker
- 6550.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- PO Box 309, Grand Cayman, Cayman Islands, KY1-1104
- Phone
- 813 886 6500
- Website
- polaris-group.com
About Polaris Group
Polaris Group, together with its subsidiaries, offers biotechnology, pharmaceutical testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It also offers healthcare consulting, staffing, and MDS solutions. The company was incorporated in 2006 and is based in Grand Cayman, Cayman Islands.
Polaris Group management
6- Mr. Xianzhe ChenChairman & CEO · born 1950
- Mr. Jack FitzgibbonsPresident & COO
- Mr. Ray Wu M.B.A.Chief Financial Officer
- Chien-Hsing ChangChief Strategy Officer
- Kevin WuChief Information Security Officer
- Yuexun WuDeputy General Manager